| Sep 24 |
Market Chatter: Lenders Commit Over $11 Billion for Buyout of Sanofi Health Unit
|
| Sep 24 |
Lenders Line Up Over €10 Billion for Sanofi Health Unit Buyout
|
| Sep 23 |
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
|
| Sep 23 |
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
|
| Sep 23 |
Sanofi CEO still considering how to split consumer biz, hopes to keep a stake
|
| Sep 23 |
Ventyx stock climbs 8% on $27M Sanofi investment
|
| Sep 23 |
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
|
| Sep 23 |
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
|
| Sep 20 |
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
|
| Sep 20 |
Sanofi sees positive data in phase 3 tolebrutinib multiple sclerosis study
|
